TIDMNSCI
RNS Number : 2073U
NetScientific PLC
27 July 2020
NetScientific plc
("NetScientific" or the "Company")
PDS Biotechnology Announces Preclinical Data for PDS0203, a
T-Cell Activating Recombinant Protein Vaccine Against COVID-19
Versamune-CoV-2 (PDS0203) generated high levels of robust,
long-lasting CD8 (killer) T-cell responses and potent neutralizing
antibody responses within 14 days of vaccination
NetScientific plc (AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces that its portfolio company PDS
Biotechnology Corporation ("PDS") (Nasdaq: PDSB) today announced
preclinical data for its COVID-19 vaccine candidate,
Versamune-CoV-2 (PDS0203). PDS0203 pairs the Versamune(R) platform
with a recombinant protein recognized by the human immune system
that is derived from the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19. The protein
included in PDS0203 encompasses SARS-CoV-2 sections that induce an
antibody response, as well as sections that are recognized by CD8
and CD4 T-cells.
PDS Biotech has generated robust preclinical data confirming
that PDS0203 elicits induction of highly active and potent
virus-specific CD8 killer and CD4 helper T-cells within 14 days of
treatment. Importantly, the study also demonstrated induction of
the long-lasting virus-specific memory T-cells necessary for longer
term protection. PDS0203 demonstrated a 30-45 fold increase in
COVID-19 specific T-cells by Day 14 when compared to the vaccine
without Versamune(R). These preclinical studies also confirmed
induction of strong anti-SARS-CoV-2 neutralizing antibodies within
14 days, with a 20-25-fold increase when compared to the vaccine
without Versamune(R). Lastly, these preclinical studies showed a
further substantial increase in neutralizing antibody levels
continuing more than 30 days after vaccination. PDS Biotech plans
to submit details of the preclinical studies to a peer reviewed
scientific journal.
As previously announced, the Company has also initiated
preclinical development of Versamune(R)-CoV-2FC (PDS0204), a
COVID-19 vaccine candidate being developed in partnership with
Brazil-based Farmacore Biotechnology, which combines the
immune-activating Versamune(R) platform with a Farmacore-developed
SARS-CoV-2 recombinant fusion protein.
NetScientific holds 7.18% of PDS' undiluted share capital.
Dr. Ilian Iliev, Chief Executive Office of the Company said: "We
are delighted with the excellent progress made by PDS Biotechnology
since the investment anchored by NetScientific earlier this year,
and that it is contributing to the global efforts towards the
COVID-19 pandemic."
The full details of the announcement are set out below and can
be found he re:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/406-iotechnnouncesreclinicalatafor0203ael20200727
# # #
PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell
Activating Recombinant Protein Vaccine Against COVID-19
Versamune-CoV-2 (PDS0203) generated high levels of robust,
long-lasting CD8 (killer) T-cell responses and potent neutralizing
antibody responses within 14 days of vaccination
FLORHAM PARK, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company's proprietary
Versamune(R) T-cell activating technology, today announced
preclinical data for its COVID-19 vaccine candidate,
Versamune-CoV-2 (PDS0203). PDS0203 pairs the Versamune(R) platform
with a recombinant protein recognized by the human immune system
that is derived from the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19. The protein
included in PDS0203 encompasses SARS-CoV-2 sections that induce an
antibody response, as well as sections that are recognized by CD8
and CD4 T-cells.
PDS Biotech has generated robust preclinical data confirming
that PDS0203 elicits induction of highly active and potent
virus-specific CD8 killer and CD4 helper T-cells within 14 days of
treatment. Importantly, the study also demonstrated induction of
the long-lasting virus-specific memory T-cells necessary for longer
term protection. PDS0203 demonstrated a 30-45 fold increase in
COVID-19 specific T-cells by Day 14 when compared to the vaccine
without Versamune(R). These preclinical studies also confirmed
induction of strong anti-SARS-CoV-2 neutralizing antibodies within
14 days, with a 20-25-fold increase when compared to the vaccine
without Versamune(R). Lastly, these preclinical studies showed a
further substantial increase in neutralizing antibody levels
continuing more than 30 days after vaccination. PDS Biotech plans
to submit details of the preclinical studies to a peer reviewed
scientific journal.
"Recent COVID-19 research has highlighted the critical
importance of developing vaccines capable of generating high levels
of targeted CD8 and CD4 T-cells, in addition to neutralizing
antibodies, to achieve durable protection against COVID-19
infection. Our preclinical data shows PDS0203's ability to rapidly
induce both protective antibodies and long-lasting T-cells specific
for COVID-19," commented Dr. Frank Bedu-Addo, CEO of PDS Biotech,
"Due to the mechanism by which Versamune(R) activates a
disease-specific immune response, our PDS0101 program demonstrated
successful translation of T-cell induction and safety data from
preclinical models to humans. We therefore believe that this
encouraging PDS0203 preclinical data may similarly translate to
humans. If so, then it may present unique potential to provide the
breadth and level of immune responses necessary for a safe and
effective vaccine with long-term protection against COVID-19."
As previously announced, the Company has also initiated
preclinical development of Versamune(R)-CoV-2FC (PDS0204), a
COVID-19 vaccine candidate being developed in partnership with
Brazil-based Farmacore Biotechnology, which combines the
immune-activating Versamune(R) platform with a Farmacore-developed
SARS-CoV-2 recombinant fusion protein.
About the Versamune(R) technology platform
The Versamune(R) technology is based on proprietary immune
activating lipids that uniquely activate an important immunological
signaling pathway, called the Type 1 interferon signaling pathway,
known to be important in the induction of both anti-viral and
anti-tumor immune responses. It also promotes efficient access of
the disease-specific immunologically recognized protein (antigen)
into two important immunological pathways called the Class I and II
MHC pathways, therefore enabling powerful induction and activation
if CD8 (Killer) and CD4 (helper) T-cells that can recognize, kill
and protect against the specific disease. The technology is
protected by multiple international composition and application
patents.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a
growing pipeline of cancer immunotherapies and infectious disease
vaccines based on the Company's proprietary Versamune(R) T-cell
activating technology platform. Versamune(R) effectively delivers
disease-specific antigens for in vivo uptake and processing, while
also activating the critical type 1 interferon immunological
pathway, resulting in production of potent disease-specific killer
T-cells as well as neutralizing antibodies. PDS Biotech has
engineered multiple therapies, based on combinations of
Versamune(R) and disease-specific antigens, designed to train the
immune system to better recognize disease cells and effectively
attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0203
PDS0203 is a COVID-19 vaccine candidate that combines the
utility of the Versamune(R) platform with a recombinant native
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
protein. The World Health Organization (WHO) declared the COVID-19
outbreak caused by a novel coronavirus, Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), a global health emergency in
January of 2020. Within three months of initial discovery COVID-19
was declared a global pandemic, reflecting alarming levels of
spread and severity and resulting in unprecedented action by local
and national governments to restrict the movement of citizens to
contain the spread. Building immunity to the disease is the key to
stopping its spread. A COVID-19 vaccine would train the immune
system to recognize and destroy the virus without the vaccinated
person getting sick.
About PDS0204
PDS0204 is a COVID-19 vaccine candidate that combines the
utility of the Versamune(R) platform with a Farmacore-developed
recombinant fusion protein of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO)
declared the COVID-19 outbreak caused by a novel coronavirus,
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a
global health emergency in January of 2020. Within three months of
initial discovery COVID-19 was declared a global pandemic,
reflecting alarming levels of spread and severity and resulting in
unprecedented action by local and national governments to restrict
the movement of citizens to contain the spread. Building immunity
to the disease is the key to stopping its spread. A COVID-19
vaccine would train the immune system to recognize and destroy the
virus without the vaccinated person getting sick.
# # #
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Following the
publication of this announcement, this inside information is now
considered to be in the public domain.
For more information, please contact:
NetScientific
Ilian Iliev, CEO Tel: +44 (0)20 3514 1800
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666
MO PR ADVISORY (Press Contact)
Mo Noonan Tel: +44 (0)78 7644 4977
About NetScientific
NetScientific PLC is a transatlantic healthcare IP
commercialisation Group focused on technologies and companies that
have the potential to treat chronic disease and significantly
improve the health and well-being of people.
For more information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESEALXXAEDEEFA
(END) Dow Jones Newswires
July 27, 2020 10:06 ET (14:06 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024